Talking Points
A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe.
Episodes
The BHF PROTECT-TAVI Trial
Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.
The FAME 3 Trial
William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
The TRILUMINATE Pivotal Trial
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
The PRAGUE-25 Study
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
The BETAMI-DANBLOCK Trial
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
The PROCTOR Trial
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
The SELUTION DeNovo Trial
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
The VESALIUS-CV Trial
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
The META-AF Trial
Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
Evolution of Pharmacotherapy in STEMI
How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.
The CorCMR Trial
Colin Berry and C. Michael Gibson discuss whether stress CMR imaging is helpful in patients with angina and no obstructive CAD.
The TUXEDO-2 Trial
Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.
The FLOW Trial
C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
The 2024 ESC CCS Guidelines
Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.
The My Heart Your Heart Trial
Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.
The FAVOR III Europe Trial
Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.
The FLOW Trial
C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
STORM-PE TRIAL
James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).
The EARLY TAVR and TAVR UNLOAD Trials
For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.
The EPIC-CAD Trial
Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.
The ECLIPSE Trial
Ajay Kirtane and C. Michael Gibson discuss how orbital atherectomy compares with balloon angioplasty for severely calcified coronary arteries before DES implantation.
The CLEAR SYNERGY (OASIS 9) Trial
Does long-term colchicine benefit patients after acute MI? C. Michael Gibson and Sanjit Jolly discuss.
097245
The NOTION-3 Trial
Mamas Mamas talks to Jacob Thomsen Lønborg about how PCI affects outcomes for patients with stable CAD undergoing TAVI.
TMVR in the Heart Failure Paradigm
Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.
The ABYSS Trial
Johanne Silvain, Gilles Montalescot, and C. Michael Gibson discuss the effects of beta-blocker interruption in post-MI patients.
Patient Selection and Treatment Goals
Patient selection is important for transcatheter interventions and impacts result success. This discussion focuses on defining what treatment goals should be, limitations of current interventions, and identifying appropriate transcatheter patients.
Women's Health Study: Biomarkers
Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
Echocardiography and Quality Data
Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices.
Insights on Intrepid 2-Yr Mitral TF EFS
The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the transcatheter landscape.
New ESC Guidelines for AF
Renate Schnabel, Ruben Casado Arroyo, and Mamas Mamas discuss the atrial fibrillation recommendations unveiled at ESC Congress 2024.
The STEEER-AF Trial
Dipak Kotecha talks to C. Michael Gibson about whether educating healthcare providers on rhythm-control therapy affects guideline adherence and stroke outcomes.
The EPIC-CAD Trial
Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.
Acute Coronary Care in Ethiopia
Mamas Mamas talks to Tesfaye Telila about the landscape of acute coronary care in Ethiopa, where just a few dozen cardiologists contend with a population of 120 million people.
The POPular PAUSE TAVI Trial
Should we stop anticoagulation therapy before TAVI in patients with aortic stenosis? Dirk-Jan van Ginkel and C. Michael Gibson discuss.
The SENIOR-RITA Trial
Vijay Kunadian talks to C. Michael Gibson about using an invasive or conservative strategy for older patients with NSTEMI.
The REDUCE-AMI Trial
Troels Yndigegn, Sripal Bangalore, and Mamas Mamas discuss whether beta-blockers still benefit patients with acute MI and preserved ejection fraction.
The EARTH-STEMI Trial
Gianluca Campo and C. Michael Gibson compare complete versus culprit-only revascularization in older STEMI patients.
The SCOFF Trial
David Ferreira talks to C. Michael Gibson about the latest data showing patients don't need to fast ahead of cardiac catheterization.
The RESHAPE-HF2 and MATTERHORN Trials
Mamas Mamas, Stefan Anker, and Volker Rudolph talk about their studies of MitraClip for functional MR in patients with heart failure.
The EMPACT-MI Trial
Javed Butler and C. Michael Gibson discuss the trial testing early empagliflozin after acute MI.
The PROACT Trial
Talking with C. Michael Gibson, David Austin reviews the phase III trial of enalapril for anthracycline-induced cardiotoxicity in lymphoma and breast cancer patients.
The ORBITA-COSMIC Trial
Rasha Al-Lamee and Michael Foley sit down with Mamas Mamas to discuss data on an implantable coronary sinus reducer that can ease symptoms in patients with refractory angina.
The REVIVED-BCIS2 Randomized Trial
Looking at the REVIVED-BCIS2 results, Divaka Perera and C. Michael Gibson discuss the relationship between myocardial viability, PCI, and outcomes.
Ketogenic Diet and Cardiovascular Risk
Iulia Iatan talks to C. Michael Gibson about how a low-carbohydrate, high-protein diet can increase plasma lipid levels and cardiovascular risk.
The CLEAR Outcomes Trial
Steven Nissen and C. Michael Gibson discuss using bempedoic acid to reduce MACE in statin-intolerant patients with high cardiovascular risk.
Inflammatory Risk in Statin-Treated Patients
Pooling data from the PROMINENT, REDUCE-IT, and STRENGTH trials, Paul Ridker and C. Michael Gibson discuss the residual inflammatory risks for patients treated with statins.
The BUDAPEST CRT Upgrade Trial
Béla Merkely and C. Michael Gibson discuss the results of a CRT-D upgrade versus ICD alone for HFrEF patients with right ventricular pacing.
The HEART-FID Trial
Robert Mentz and C. Michael Gibson discuss the latest trial to address whether iron supplementation, this time with ferric carboxymaltose, improves outcomes for patients with HF and iron deficiency.
The FIRE Study
Simone Biscaglia and C. Michael Gibson discuss physiology-guided complete revascularization versus culprit-only PCI for elderly patients with acute MI.
The ECLS-SHOCK Trial
Holger Thiele and C. Michael Gibson discuss the impact of VA-ECMO on patients with acute MI and advanced cardiogenic shock.
The STOPDAPT-3 Trial
Masahiro Natsuaki and C. Michael Gibson discuss this latest randomized comparison of prasugrel monotherapy and DAPT with aspirin for patients undergoing PCI.
The ILUMIEN IV Trial
Ziad Ali and C. Michael Gibson take a deeper dive into this comparison of OCT- and angiography-guided PCI.
OCT vs IVUS vs Angiography: A Meta-analysis
Gregg Stone and C. Michael Gibson discuss an updated meta-analysis addressing intravascular imaging in DES implantation.
The ATTRibute-CM Trial
Julian Gillmore and C. Michael Gibson discuss the efficacy of acoramidis for patients with transthyretin amyloid cardiomyopathy.
The ADVENT Trial
Vivek Reddy and C. Michael Gibson compare pulsed field ablation versus thermal ablation for patients with paroxysmal atrial fibrillation.
The ARAMIS Trial
Mathieu Kerneis and C. Michael Gibson compare outcomes of patients treated with anakinra, a new therapy for acute myocarditis, or placebo.
The NITRATE-CIN Trial
Dan Jones and C. Michael Gibson discuss whether inorganic nitrate reduces contrast-induced nephropathy after angiography in ACS patients.
The DICTATE-AHF Trial
Zachary Cox and C. Michael Gibson discuss whether early dapagliflozin initiation is safe and effective for patients with acute heart failure.
The RIGHT Trial
Shaoping Nie, Gilles Montalescot, and C. Michael Gibson discuss prolonged anticoagulation after primary PCI for patients with MI.
Four-Year Results: The EVOLUT Low Risk Trial
Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.
The AGENT IDE Trial
Robert W. Yeh and C. Michael Gibson discuss the primary outcomes of this eagerly awaited trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis.
The TRISCEND II Trial
Susheel K. Kodali and C. Michael Gibson discuss transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation.
The VIVA Trial
Josep Rodés-Cabau and C. Michael Gibson discuss the benefits of TAVI versus SAVR in patients with severe aortic stenosis and small aortic annuli.
The SELECT Trial
A. Michael Lincoff and C. Michael Gibson discuss the cardiovascular impact of semaglutide in patients with overweight or obesity but without diabetes.
The MINT Trial
Jeffrey Carson and Serge Korjian discuss restrictive versus liberal blood transfusion in patients with MI and anemia.
The ORBITA-2 Trial
Christopher Rajkumar, Rasha Al-Lamee, and C. Michael Gibson discuss this randomized trial of PCI versus a placebo procedure for stable angina.
The ARIE-HM3 Trial
Mandeep Mehra and C. Michael Gibson discuss whether or not aspirin is needed for patients with left ventricular assist devices in advanced heart failure.
The AZALEA - TIMI Trial
Christian T. Ruff and C. Michael Gibson discuss the primary results of a randomized trial testing the efficacy of abelacimab versus rivaroxaban for stroke prevention in atrial fibrillation.
The heart-1 Trial of VERVE-101
Andrew Bellinger, Sek Kathiresan, and C. Michael Gibson talk about the phase 1b trial of what investigators hope may be a one-time genetic fix for hyperlipidemia.
Lepodisiran Phase I Trial
Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).
CLEAR Outcomes Subanalysis
Paul Ridker and C. Michael Gibson discuss whether residual inflammatory risk or residual cholesterol risk is a more effective predictor of CV events among patients treated with statins.
The AXIOMATIC - SSP Trial
Mike Sharma and C. Michael Gibson discuss managing acute thromboembolic events in secondary stroke using antithrombotic treatment with factor XIa inhibition.
The EBRAVE - AF Trial
Axel Bauer and C. Michael Gibson talk about whether smartphone-based screening can effectively detect atrial fibrillation in elderly, at-risk patients.
The INVICTUS Trial
Ganesan Karthikeyan and C. Michael Gibson compare the efficacy of rivaroxaban versus vitamin K agonists for patients with rheumatic heart disease associated atrial fibrillation
The FRAME-AMI Trial
Joo-Yong Hahn and C. Michael Gibson compare FFR with angiography-guided PCI for patients with acute myocardial infarction and multivessel disease.
MASTER DAPT: Long-Term Results
Marco Valgimigli and C. Michael Gibson discuss the long-term follow-up results from MASTER DAPT, which compared the outcomes of high bleeding risk patients randomized to either abbreviated or standard antiplatelet therapy.
Episode 180: The PANTHER Trial
Marco Valgimigli and C. Michael Gibson discuss the PANTHER trial, which compared P2Y12 inhibitor monotherapy with aspririn monotherapy in patients with coronary artery disease.
Radial vs. Femoral Access for PCI: Meta-Analysis
Giuseppe Gargiulo and C. Michael Gibson discuss whether the choice of radial or femoral artery access impacts the risk of mortality and major bleeding for patients undergoing coronary procedures.
Episode 181: ACT Outpatient and Inpatient Trials
Sanjit Jolly and C. Michael Gibson discuss if colchicine and rivaroxaban plus aspirin can slow disease progression in patients hospitalized with COVID-19.
Recommended
Hard Knocks Podcast
Effective Weight Loss for Moms | High protein, Strength Training, Lose Weight, Meal Planning, Fat Loss, Healthy Habits
The Human-Animal Connection - Pet Life Radio Original
Infinite Health with Dr. Arasi Maran
The Daily
World News Tonight with David Muir
English Vocabulary Help
The Joe Rogan Experience
TED Talks Daily
Learn English B1 with Daily News | English Listening Practice
Talk About Talk - Executive & Leadership Communication Skills
English with Olivia | Slow Conversations & Vocabulary
